Drug Profile
Adalimumab biosimilar - ISU Abxis
Alternative Names: ISU202Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator ISU Abxis
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders; Rheumatoid arthritis
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for research development in Immunological-disorders in South Korea (SC, Injection)
- 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in South Korea (SC, Injection)
- 31 Dec 2013 Early research in Immunological disorders in South Korea (SC)